Hematology
Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.
Recent Discussions
Do you consider testing and treating IDA in unexplained thrombocytopenia?
Iron deficiency often causes thrombocytosis, and in fact, probably is the most common cause of reactive thrombocytosis encountered in clinical practice. With very severe iron deficiency, thrombocytopenia can be seen. I have seen it in rare patients presenting with hemoglobin levels about 3 gm/dL or ...
What are your top takeaways in Hematology from ASCO 2025?
New exciting data on NDMM, MRD, and immunotherapies. The myeloma field is moving forward fast. Lots of change to come in the (near) future. Better for patients.
Do you defer bispecific antibody therapy in CAR-T-eligible patients with relapsed myeloma to keep CAR-T viable as a future option?
A Carvykti CAR-T has the highest response proportion and may have the longest PFS in patients with relapsed myeloma who have received one prior line of therapy, and my general approach is to always use my best treatment first, as you never know whether this will be the patient's last line of therapy...
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
Routine monitoring of triglyceride levels is not considered standard practice during pegaspargase therapy. Although hypertriglyceridemia is a common side effect of asparaginase treatment, it typically has no significant clinical impact on management decisions or future use of asparaginase. The condi...
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
CD20xCD3 bispecific antibodies are a very promising class of drugs available for relapsed DLBCL, with response rates ~50-60% as monotherapy and approaching 70% in combination with chemotherapy (GemOx). Glofitamab or epcoritamab in combination with GemOx is available in the 2nd-line setting if the pa...
Would you treat an early stage transformed DLBCL from indolent lymphoma in the same way as a standard, newly diagnosed de novo DLBCL?
To my knowledge, all studies in limited-stage LBCL excluded prior indolent lymphoma. Therefore, we do not have prospective data to support shorter courses of CIT. It will be an interesting subject of investigation. However, given that, in general, cell of origin or MYC double-hit status does not rea...
In a patient with persistent, otherwise unexplained mild anemia (e.g., Hb 12 g/dL) and a pathogenic somatic mutation identified on peripheral blood myeloid NGS, when do you pursue bone marrow biopsy to evaluate for CCUS/MDS rather than monitoring expectantly?
In situations where a mild but otherwise unexplained clonal cytopenia is present, the decision to pursue a bone marrow biopsy can depend on the impact that the bone marrow results would have on clinical care and the likelihood of making a diagnosis. For example, a mild stable anemia in an older pati...
If tafasitamab/lenalidomide plus R-CHOP (frontMIND) is approved/utilized for frontline treatment, how would you approach second-line therapy in transplant-ineligible patients with relapsed/refractory DLBCL?
I do not think my approach to transplant-ineligible R/R DLBCL will significantly change, other than not using Tafasitamab-Len. I will still consider CAR-T cell therapy as a treatment option, as Tafa does not seem to affect the efficacy of CD19 CAR-T (Sakemura et al., PMID 37879074, and also Bastos-O...
What GDMT do you recommend for patients with AL amyloidosis and systolic heart failure?
Great question, and Dr. @Dr. First Last has provided a great answer. There are a few things that I will add to it. Yes, late-stage cardiac amyloid patients are much more likely to be intolerant of GDMT, but this is a heterogeneous group that may or may not have comorbid CAD, arrhythmias, etc., and m...
With the recent FDA approval of nipocalimab and the emerging LUMINA 2 data for rilzabrutinib, what is your approach to wAIHA refractory to or relapsed after steroids and rituximab?
Probably because of its rarity (1–3 new cases per 100,000 people), we often joke that there are more treatments at our disposal for the management of wAIHA than the number of cases any hematologist sees on an annual basis—or even during their lifetime. A partial list includes typical first-line trea...